From Scientific Complexity to Strategic Consulting

Life Sciences Review | Wednesday, September 30, 2026

Strategy Must Account for Scientific Complexity

Life sciences companies operate in an environment where a promising scientific concept can face years of development, extensive evidence requirements and substantial commercial uncertainty. A decision made during research can influence clinical development, regulatory submissions, manufacturing requirements and eventual market access.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Consulting therefore has a different role in life sciences than in many other industries. Advisors need to understand the science behind a product while also assessing development pathways, competitive conditions, regulatory expectations and commercial implications.

Deloitte's 2026 Life Sciences Outlook identifies pricing and access pressures, competition, geopolitical uncertainty, supply chain risks and regulatory changes among the factors shaping company strategies. The research also points to partnerships, productivity and disciplined investment as important areas of focus.

Regulatory Strategy Starts Earlier

Regulatory considerations increasingly influence decisions well before a product reaches a submission stage. Developers must determine what evidence is needed, how studies should be designed and how emerging scientific approaches can fit within regulatory expectations.

FDA activity during 2026 illustrates the breadth of this environment. The agency issued final guidance on modelinformed drug development and released revised draft guidance covering substantial evidence of effectiveness and master protocols. It has also published guidance on new approach methodologies and individualized therapies.

Consultants can help companies interpret these developments and connect regulatory requirements with development planning. The value lies less in simply tracking guidance and more in understanding how a regulatory change may affect study design, evidence generation, timelines and investment decisions.

Evidence Generation Is Becoming More Sophisticated

Clinical development is moving toward increasingly complex evidence models. Master protocols, quantitative systems pharmacology, real-world data and other analytical approaches can influence how developers generate evidence.

FDA's June 2026 actions on modernizing clinical development include guidance on master protocols and quantitative systems pharmacology. The agency notes that master protocols can coordinate multiple investigations under one framework and potentially reduce duplicated infrastructure and data collection.

This creates demand for consulting expertise that spans statistics, clinical research, regulatory affairs, data science and therapeutic-area knowledge. Companies need to understand not only whether a particular method is technically possible but whether it is appropriate for the intended development question.

Model-informed drug development provides another example. FDA's final M15 guidance establishes a harmonized framework for planning, evaluating and documenting MIDD evidence and related regulatory interactions.

Commercial Decisions Begin Before Approval

A scientifically successful product still needs a viable path to patients. Market size, competitive products, pricing, reimbursement, distribution and healthcare-provider adoption can all influence commercial potential.

Life science consultants increasingly work across these areas, helping companies evaluate portfolios, identify market opportunities, assess competitors and prepare commercialization strategies. For emerging biotechnology companies, such analysis can also influence partnering decisions and fundraising narratives.

“Consulting is consequently becoming less about delivering isolated recommendations and more about helping life science organizations make informed choices across the full development and commercialization journey.”

Market access is particularly important when innovative therapies carry complex evidence or pricing considerations. Regulatory approval establishes whether a product can be marketed, but it does not automatically determine how readily healthcare systems will adopt or reimburse it.

That distinction makes commercial strategy an important component of development planning rather than a function reserved for the period immediately before launch.

Specialization Is Becoming More Valuable

The life sciences sector contains distinct technical and regulatory environments. A cell and gene therapy program has different manufacturing and evidence requirements from a conventional small-molecule medicine. Medical devices, diagnostics, digital health products and biotechnology platforms introduce their own considerations.

FDA's 2026 guidance for cellular and gene therapy products illustrates this specialization. Its recommendations cover areas including regulatory review, clinical development, pharmacology and toxicology, and chemistry, manufacturing and controls.

Consulting firms therefore increasingly organize expertise around therapeutic areas, technologies and development stages. Specialized knowledge can be particularly important for companies working on emerging modalities where established development pathways may not fully address the scientific or regulatory questions involved.

Technology Changes the Consulting Model

Artificial intelligence and advanced analytics are also affecting how consulting work is performed. Life science companies are exploring AI across research, clinical development, manufacturing and commercial functions, while consultants are using data tools to examine larger information sets and support scenario analysis.

Deloitte's 2026 midyear research found that life science leaders were focusing on productivity, commercial performance, investment discipline, partnerships, resilience and AI deployment while navigating continued external uncertainty.

Technology can accelerate analysis, but consulting decisions still require scientific interpretation and context. Data quality, model limitations and regulatory expectations can determine whether an analytical result is useful enough to influence a business decision.

The strongest consulting engagements therefore combine technological capability with subject-matter expertise rather than treating digital tools as a substitute for domain knowledge.

From Advice to Connected Decision-Making

Life science consulting is becoming increasingly interconnected with the decisions companies make across the product lifecycle. Research strategy can affect regulatory positioning. Clinical evidence can influence market access. Manufacturing choices can affect scalability. Commercial assumptions can change the value assigned to an early-stage asset.

That interconnectedness is increasing the importance of multidisciplinary advisory models. Companies may need scientific, regulatory, clinical, commercial and operational perspectives at different points in the same program.

For consulting firms, the challenge is maintaining enough specialization to understand complex science while connecting that expertise to broader business objectives. For life science companies, the objective is to use external expertise where it can improve the quality and clarity of critical decisions.

The sector's changing environment makes that role increasingly relevant. Scientific progress is creating new opportunities, while regulatory expectations, evidence standards and commercial pressures continue to evolve. Consulting is consequently becoming less about delivering isolated recommendations and more about helping life science organizations make informed choices across the full development and commercialization journey.

More in News

The Expanding Role of Professional Training in Life Sciences

The life sciences industry, encompassing pharmaceuticals, biotechnology, medical devices, and related fields, is an ever-evolving sector at the forefront of human health and well-being. Integral to its continuous advancement is a robust and adaptive ecosystem of training services. These services are crucial for equipping professionals with the specialised knowledge and skills required to navigate complex scientific, technological, and regulatory landscapes. Evolving Modalities and Diverse Curricula At its core, life science training aims to foster a highly skilled workforce, from entry-level technicians to seasoned researchers and executives. This encompasses a broad spectrum of educational offerings, ranging from foundational scientific principles to advanced technical proficiencies and intricate regulatory compliance. Traditional classroom-based instruction remains relevant, particularly for in-depth theoretical understanding and the delivery of structured curricula. However, the industry has seen a significant proliferation and diversification of training modalities, driven by technological advancements and the need for greater accessibility and flexibility. The adaptability of professionals in embracing new training modalities is a testament to their commitment to staying current in the rapidly changing industry. E-learning platforms have emerged as a cornerstone of modern life science training. These platforms offer a wealth of on-demand courses, interactive modules, and virtual simulations, allowing professionals to learn at their own pace and from any location. This flexibility has become even more valuable in the wake of the COVID-19 pandemic, which has accelerated the adoption of remote learning in a globalised industry where continuous professional development is paramount. Live online sessions, often blending expert instruction with interactive elements, also provide a dynamic learning experience, fostering real-time engagement and discussion. Many training providers now offer a hybrid approach, combining the benefits of virtual learning with periodic in-person workshops to provide hands-on experience and facilitate networking. The content of life science training is incredibly diverse, reflecting the multifaceted nature of the industry. Core scientific disciplines such as molecular biology, biochemistry, pharmacology, and genetics form the bedrock of many programs. Beyond these fundamentals, specialised training areas are critical. For instance, in drug discovery and development, training encompasses everything from target identification and lead optimisation to clinical trial design, data management, and pharmacovigilance. Manufacturing and quality assurance are other significant domains, with courses covering Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Quality Management Systems (QMS) to ensure product safety and efficacy. Specialised Knowledge and Complementary Skills Regulatory affairs training is of paramount importance in the life sciences. Given the stringent regulations governing product development, approval, and marketing across different global jurisdictions, professionals require deep expertise in areas such as the FDA, EMA, and other regional guidelines. This includes training on regulatory submissions, post-market surveillance, and adherence to evolving compliance standards. The role of regulatory bodies in shaping the training landscape cannot be overstated, as they drive the need for continuous learning and adaptation to new standards and regulations. The rise of new modalities, such as cell and gene therapies and advanced therapy medicinal products (ATMPs), has further necessitated specialized training in their unique regulatory pathways and manufacturing considerations. Beyond scientific and regulatory knowledge, the modern life science professional requires a blend of complementary skills. Training programs increasingly incorporate modules on data analytics, bioinformatics, and the application of artificial intelligence and machine learning in research, development, and clinical settings. The ability to interpret complex datasets, utilize computational tools for drug discovery, and leverage AI for predictive modeling is becoming essential. However, it's necessary to note that soft skills, such as effective scientific communication, technical writing, project management, and leadership, are equally vital for success in collaborative and interdisciplinary environments. The industry is recognizing the importance of these skills, and training in these areas helps professionals not only excel in their technical roles but also to articulate scientific findings, lead teams, and navigate the commercial aspects of the industry. Practical Application and Future Directions A notable trend in the life science training landscape is the increasing emphasis on practical, skill-based learning. This goes beyond theoretical knowledge to focus on the application of concepts in real-world scenarios. Many programs now offer hands-on laboratory training, virtual lab simulations, and opportunities to work on industry-relevant projects. This practical orientation ensures that graduates and professionals are not only knowledgeable but also proficient in executing tasks and solving problems encountered in their daily work. The value of these practical skills in the industry cannot be overstated, as they provide professionals with the confidence to apply their knowledge effectively. The future trajectory of life science training services is closely intertwined with the ongoing evolution of the broader industry. The accelerating pace of scientific discovery, the increasing complexity of therapeutic modalities, and the pervasive integration of digital technologies are all shaping the demand for specific skill sets. Training providers are continuously adapting their curricula to address emerging areas such as personalized medicine, digital health technologies (e.g., wearables, telemedicine), and advanced manufacturing techniques like 3D printing for medical devices. The focus will likely intensify on interdisciplinary training, bridging the gap between traditional life sciences and advanced computing, engineering, and data science. As the industry moves towards more integrated and patient-centric approaches, training will also emphasize understanding the entire product lifecycle and the broader healthcare ecosystem. ...Read more

Elevating Patient Care: The Impact of AI on Prognostic Testing

Healthcare is moving from reactive treatment to proactive care. Clinicians are looking for better ways to anticipate disease progression and facilitate timely and appropriate interventions. AI-based prognostic testing is playing an important role in this transformation to estimate the probability of future health outcomes by analyzing complex clinical information. These technologies are not intended to replace medical expertise. They would rather provide decision support tools that help healthcare professionals to process massive amounts of data more efficiently and to detect patterns that may not be obvious. AI-based prognostic solutions are being integrated into clinical workflows for risk assessment, treatment planning, patient monitoring and long-term management of care. With increased computing power and medical data, these systems are becoming more accurate, efficient and clinically relevant. Healthcare providers need more transparency about how AI systems make predictions so they can confidently interpret recommendations. Better interpretability of models supports responsible clinical use and promotes more trust in AI-assisted decision support. How Are AI-Based Prognostic Testing Solutions Advancing? Current AI systems are capable of analyzing data from sources including medical images, laboratory results, clinical records, genomic data, and physiological measurements. Bringing these datasets together gives a fuller view of a patient’s state, allowing for better clinical judgment. In clinical data, advanced algorithms may detect subtle relationships that can help healthcare professionals make predictions regarding disease progression, recovery patterns or likelihood of complications. These insights support earlier intervention and more personalized treatment strategies, but within the framework of the overall clinical decision-making process. AI systems are evolving beyond population-based models by incorporating individual patient characteristics, medical history and clinical information in real time. Therna Biosciences combines proprietary experimental data and machine learning to support the design of programmable RNA medicines. This enables clinicians to customize care plans that better fit each patient’s individual situation. As healthcare increasingly embraces precision medicine and digital transformation, AI-based prognostic testing is becoming increasingly relevant to delivering proactive, personalized and data-driven care. What Technologies Are Shaping the Future of Prognostic Testing? Analytics are being increasingly integrated with AI to support clinical decision-making. Models can be updated as new clinical evidence, research results and validated healthcare data become available, helping to keep systems relevant and support changes in medical practice. Cloud-based clinical platforms are enhancing collaboration by providing authorized healthcare teams with secure access to prognostic data, patient records and analytical tools across different care settings. Etiometry uses continuous physiologic data and clinical intelligence to help clinicians interpret patient risk in real time. Automation is increasing the efficiency of data processing by minimizing the need for manual administrative work to gather, organize and evaluate clinical information. AI-powered prognostic testing is emerging as a useful addition in the modern healthcare setting to help enable earlier risk identification, customized treatment planning, and more streamlined clinical workflows. Organizations that combine advanced AI capabilities with strong clinical validation, transparency and governance will be best placed to improve patient outcomes and form the foundation of predictive healthcare of the future. ...Read more

Proficiency Testing That Reveals Method Limits

Proficiency testing is less useful when the challenge is easy to predict. A laboratory can do well with familiar concentrations and still have weaknesses in how it chooses a method or interprets results. For life science leaders, the bigger question is whether a program can bring those weaknesses to light before they affect routine reporting. Accreditation is important, but it does not tell buyers how well the test itself has been designed. What matters is whether the scheme simply confirms that a laboratory can perform routine testing or also shows where its test system may start to struggle. Buyers therefore need enough detail on sample construction and scoring to know what a satisfactory result really says about laboratory performance. A proficiency score can look reassuring when the specimens are too simple, but it does not necessarily show how a method will perform when conditions are less predictable. A useful program should reveal how the method responds when organisms compete, analyte levels shift, matrix chemistry interferes or non-type strains make results harder to interpret. The exercise should put routine methods through a realistic test without making the conditions feel artificial. Concentration ranges should help identify where interpretation becomes difficult, while matrix choices should reflect the chemistry and microbial background laboratories actually encounter. Ready-to-test materials can reduce preparation differences too, making it easier to tell whether a poor result comes from the test system or the exercise itself. The challenge should test judgment as well. A clean result from one analyst does not tell you much about variation across the rest of the laboratory. Broader participation allows laboratories to compare performance across staff or repeated result sets without making the exercise an unreasonable budget burden. Poor scores should also lead to something useful. Reporting alone has limited value if laboratories cannot investigate an outlier and use the finding to revise a procedure. Technical dialogue becomes valuable at that stage, provided the provider helps clarify the result without taking over the laboratory’s own root-cause work. Repeated participation should then show whether corrective changes are holding rather than simply closing out a single incident. “IFM Quality Services permits multiple result submissions without extra fees, allowing broader laboratory participation in the same exercise.” Finding the right program is not always straightforward when laboratories use different microbiological methods and sample matrices. A generic exercise may not pick up problems that are specific to a particular method, especially when molecular techniques or unusual materials affect how results are interpreted. That is why buyers should check whether a program actually covers the test methods and sample types used in their laboratory, rather than relying on a standard template. The materials themselves deserve attention too. Base material, presentation format, shelf life and storage conditions can all influence the usefulness of the results. Consistent production and documented quality control should be part of the buying decision, not something left to the back office. Programs should also be reviewed over time, with sample formats changing when recurring results point to limitations in the exercise. For laboratories that expect proficiency testing to do more than confirm routine performance, IFM Quality Services is a provider worth considering. Its microbiological programs include multiple samples and different analyte levels, with real ready-to-test materials used where practical. Laboratories can also submit results multiple times without paying extra fees, making it easier for more staff to take part in the same exercise. The programs cover foods, pharmaceuticals, water and generic sample types, including samples developed for PCR-based methods. IFM produces reference materials as well as proficiency testing programs. It also runs an accredited biological testing laboratory, keeping its program design closely connected to laboratory practice. Where sample challenge and method relevance matter, IFM provides a practical option beyond straightforward pass-fail confirmation. ...Read more

Enhancing Patient Care Through Integrated Pharmacy Network Services

Healthcare organizations are increasingly focusing on improving coordination, accessibility and service efficiency to create a more connected experience for patients and providers. Integrated pharmacy network services are helping strengthen communication between pharmacies, healthcare stakeholders and patients through better-connected systems and streamlined operations. These services support smoother information exchange, improved medication management and more consistent access to pharmacy resources, enabling healthcare networks to respond more effectively to patient needs while creating a more organized approach to care delivery. Current Market Trends Shaping Integrated Pharmacy Network Services Digital transformation is becoming a significant influence on the development of integrated pharmacy network services. Pharmacy networks are increasingly adopting advanced platforms that improve operational visibility, support datadriven decision-making and enhance interactions between different points of service. These digital capabilities are helping organizations manage pharmacy activities more effectively while creating smoother workflows across healthcare networks. The shift towards personalized healthcare is also affecting the way pharmacy networks offer services to various patient groups. Organizations are increasingly looking at solutions that consider individual needs for healthcare, the treatment pathways and patient preferences. As a result, pharmacy networks are being incentivized to create more responsive service models that enhance the customer experience for those relying on pharmacy support. The use of automation and advanced pharmacy technologies is gaining attention as organizations look for ways to improve accuracy and efficiency in daily operations. Automated processes, digital tools and technology-enabled solutions are helping pharmacy networks reduce manual workloads and optimize routine activities. This trend is encouraging the adoption of modern practices that support more reliable and scalable pharmacy services. Key Challenges and Solutions in Integrated Pharmacy Network Services Regulatory disparities within healthcare jurisdictions continue to be a critical challenge that poses difficulties for the provision of integrated pharmaceutical services. This is especially evident when there are disparities within healthcare regulations, compliance requirements and standard operating procedures. Strengthening regulatory monitoring, establishing clear compliance processes and working closely with local experts can help networks navigate these complexities more effectively. Pharmacy networks also deal with sensitive healthcare data, so preserving strong data security is another big concern. Ensuring that patient records are secure and cannot be accessed or viewed by unauthorized individuals requires a high degree of security, but also constant monitoring. To combat these risks, organizations are investing in enhanced cybersecurity measures that include controlled access systems as well as ongoing auditing of information protection protocols. “Digital transformation is becoming a significant influence on the development of integrated pharmacy network services.” As networks expand into new areas, it can be difficult to keep practices consistent between the multiple pharmacy locations. This variance in operating procedures, service protocols and the availability of resources can result in reduced uniformity throughout the network. To combat this, organizations are adopting standard operating procedures, forming common service frameworks and driving regular quality reviews to achieve better consistency across locations. Managing costs associated with network expansion and service improvement can also create pressure for pharmacy organizations. Investments in infrastructure, workforce requirements and operational upgrades may require careful financial planning. Organizations are responding by evaluating resource allocation, improving process efficiency and adopting strategies that support better cost management. A continuing key challenge for integrated pharmacy network services is developing a competent workforce capable of managing complex pharmacy operations. Differences in technical knowledge, operational experience and role-specific expertise can influence service effectiveness. Organizations are responding through professional training programs, skill enhancement initiatives and knowledge-sharing practices that help employees perform their responsibilities more effectively. Diligent quality control can also become difficult when organizations must juggle multiple service points and operational processes as part of integrated pharmacy networks. Inconsistencies in performance standards or divergences in internal practices can impair overall reliability. To address this challenge, organizations have developed quality assurance frameworks, performance monitoring systems and regularly operational evaluations to ensure consistent service delivery. Future Prospects and Innovations Future opportunities for integrated pharmacy network services are expected to expand as healthcare systems continue to adopt more connected and outcome-focused service models. Organizations are likely to explore broader pharmacy networks that support stronger integration with wider healthcare delivery systems while responding to changing industry expectations. This direction is expected to create new opportunities for service providers to strengthen their market presence and broaden the scope of pharmacy network services. The future innovation is expected to focus on creating more intelligent pharmacy network ecosystems that strengthen planning, coordination and long-term operational agility. Organizations are likely to place greater emphasis on predictive service planning, adaptive resource management and more responsive network strategies to address changing healthcare demands. These developments are expected to encourage more proactive decision-making and support increasingly flexible pharmacy network operations. The long-term outlook for integrated pharmacy network services remains encouraging as the industry continues to evolve alongside broader healthcare transformation. Continued progress is expected to strengthen the strategic role of pharmacy networks within healthcare delivery while encouraging greater collaboration, wider industry participation and ongoing innovation. This direction is likely to reinforce the importance of integrated pharmacy network services in supporting the future development of healthcare systems. ...Read more

Specials

From Scientific Complexity to Strategic Consulting